Published 2016 | Version v1
Publication Metadata-only

Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants.

Creators

Contributors

Additional details

Identifiers

URL
http://hdl.handle.net/11567/869988
URN
urn:oai:iris.unige.it:11567/869988

Origin repository

Origin repository
UNIGE